The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 31, 2023

Filed:

Apr. 05, 2017
Applicant:

Eli Lilly and Company, Indianapolis, IN (US);

Inventors:

Bharvin Kumar Patel, Indianapolis, IN (US);

Michele C. Smith, Indianapolis, IN (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61P 35/02 (2006.01); A61P 15/08 (2006.01); A61P 43/00 (2006.01); A61K 31/444 (2006.01); A61K 31/4745 (2006.01); A61K 31/55 (2006.01);
U.S. Cl.
CPC ...
A61K 31/55 (2013.01); A61K 31/4745 (2013.01); A61P 35/00 (2018.01);
Abstract

Medicaments for use in treating T-cell acute lymphoblastic leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, breast cancer, ovarian cancer, melanoma, lung cancer, pancreatic cancer, glioblastoma, sarcoma, desmoid tumors, adenoid cystic carcinoma, colorectal cancer, head and neck cancer, cervical cancer, prostate cancer, liver cancer, or skin cancer in a patient comprising combination therapy with 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-methyl-2-oxoethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof, and 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof.


Find Patent Forward Citations

Loading…